GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+5.59%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$144M
AUM Growth
+$144M
(+30%)
Cap. Flow
+$30.3M
Cap. Flow
% of AUM
21.1%
Top 10 Holdings %
Top 10 Hldgs %
31.75%
Holding
94
New
35
Increased
11
Reduced
9
Closed
23
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$5.22M |
| 2 |
Zimmer Biomet
ZBH
|
$5.03M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$4.49M |
| 4 |
AGN
ALLERGAN INC
AGN
|
$4.46M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$4.06M |
Top Sells
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
$6.17M |
| 2 |
Cooper Companies
COO
|
$5.42M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$5.24M |
| 4 |
Boston Scientific
BSX
|
$5.11M |
| 5 |
Insmed
INSM
|
$4M |
Sector Composition
| 1 | Healthcare | 80.91% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Viatris
VTRS
$12.3B
| – | – |
0
| – | – |
|
77
Vanda Pharmaceuticals
VNDA
$279M
| – | – |
0
| – | – |
|
|
78
Teva Pharmaceuticals
TEVA
$21.5B
| – | – |
-100,000
| Closed | -$5.24M |
|
79
SPDR S&P 500 ETF Trust
SPY
$656B
| – | – |
0
| – | – |
|
80
Regeneron Pharmaceuticals
REGN
$59.8B
| – | – |
-7,500
| Closed | -$2.12M |
|
|
81
Insmed
INSM
$30.3B
| – | – |
-200,000
| Closed | -$4M |
|
82
Inovio Pharmaceuticals
INO
$144M
| – | – |
0
| – | – |
|
83
Amicus Therapeutics
FOLD
$2.42B
| – | – |
-600,000
| Closed | -$2M |
|
84
Catalyst Pharmaceutical
CPRX
$2.42B
| – | – |
-437,296
| Closed | -$1.11M |
|
|
85
Cooper Companies
COO
$13.3B
| – | – |
-40,000
| Closed | -$5.42M |
|
|
86
Boston Scientific
BSX
$159B
| – | – |
-400,000
| Closed | -$5.11M |
|
87
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
0
| – | – |
|
|
AVDL
88
Avadel Pharmaceuticals
AVDL
$1.42B
| – | – |
-75,000
| Closed | -$1.13M |
|
89
Arcturus Therapeutics
ARCT
$467M
| – | – |
0
| – | – |
|
90
Accuray
ARAY
$165M
| – | – |
-250,000
| Closed | -$2.2M |
|
91
AbbVie
ABBV
$374B
| – | – |
0
| – | – |
|
92
Agilent Technologies
A
$35.5B
| – | – |
0
| – | – |
|